Citations 22
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Catalano, John, Belch, Andrew , Cavo, Michèle , Pinto, Antonello, Banos, Anne , Tiab, Mourad, Delforge, Michel , Cavenagh, Jamie, Lee, Je‐Jung , Chen, Christine , Oriol, Albert , Rubia, Javier de la , White, Darrell , Binder, Daniel, Moreau, Philippe , Perrot, Aurore , Arnulf, Bertrand , Qiu, Lugui , Roussel, Murielle , Boyle, Eileen M. , Manier, Salomon , Mohty, Mohamad , Avet‐Loiseau, Hervé , Leleu, Xavier , Ervin‐Haynes, Annette, Chen, Guang , Houck, Vanessa, Benboubker, Lotfi , Hulin, Cyrille , Pinto, Antonio , Moreau, Philippe , Perrot, Aurore , Boyle, Eileen M , Facon, Thierry T.F. , Dimopoulos, Meletios Α. , Dispenzieri, Angela , Pinto, Antonello, Weisel, Katja C , Ludwig, Heinz , Bahlis, Nizar Jacques , Geraldes, Catarina , Lu, Jin Ping , Anderson, Kenneth C. , Attal, Michel , Qiu, Lugui , Roussel, Murielle , Pinto, Antonio , Oriol, Albert , Mohty, Mohamad
Blood | November 17, 2017 | Volume: 131 | Issue: 3 | Pages: 301-310
Key Points Rd continuous significantly extended OS compared with MPT and resulted in comparable OS to that with Rd18 in patients with multiple myeloma. Patients achieving complete or very good partial response with Rd benefited greatly from continuous vs fixed treatment in terms of PFS.
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Wiernik, Peter H. , Moore, Timothy D., Reeder, Craig B. , Cole, Craig E. , Justice, Glen R., Voralia, Michael, Pietronigro, Dennis, Takeshita, Kenichi , Ervin‐Haynes, Annette, Zeldis, Jerome B. , Witzig, Thomas E. , Kaplan, Henry G. , Vose, Julie M.
Journal of Clinical Oncology | October 6, 2009 | Volume: 27 | Issue: 32 | Pages: 5404-5409
PurposeLenalidomide is a novel immunomodulatory agent with antiproliferative activities. Given its efficacy in a wide range of hematologic malignancies, we conducted a phase II trial (NHL-001) of single-agent lenalidomide in indolent non-Hodgkin's lymphoma (NHL).Patients and MethodsPatients with relapsed/refractory indolent NHL were eligible, with no limit on the number of previous therapies. Oral lenalidomide 25 mg was self-administered once daily on days 1 to 21 of every 28-day cycle for up to 52 weeks as tolerated, or until disease progression. The primary end point was objective response rate (ORR), with secondary end points of duration of response (DR), progression-free survival (PFS), and safety.ResultsForty-three enrolled patients were assessable for response and safety. Patients received a median of three prior systemic therapies (range, 1 to 17) and half were refractory to last therapy. ORR was 23% (10 of 43), including a 7% complete response (CR) or unconfirmed CR rate. Twenty-seven percent (six of 22) of patients with follicular lymphoma grade 1 or 2, and 22% (four of 18) with small lymphocytic lymphoma responded to therapy. Median DR was not reached, but was longer than 16.5 months with seven of 10 responses ongoing at 15 to 28 months. Median PFS for the whole group was 4.4 months (95% CI, 2.5 to 10.4 months). Adverse events were predictable and manageable; the most common grade 3 or 4 adverse events were neutropenia (30% and 16%, respectively) and thrombocytopenia (14% and 5%, respectively).ConclusionOral lenalidomide monotherapy produces durable responses with manageable adverse events in patients with relapsed/refractory indolent NHL, warranting further investigation of treatment for indolent NHL.